Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price Target

Citizens analyst Silvan Turkcan reiterates Taysha Gene Therapies (NASDAQ: TSHA ) with a Market Outperform and maintains $11 price target.